A drug made by Novartis has received approval from the Food and Drug Administration to treat benign kidney tumors related to tuberous sclerosis complex.
The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center released Wednesday.
Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.